Efanesoctocog Alfa Granted FDA Fast Track Designation for Treatment of Hemophilia A
February 18, 2021 -- The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for efanesoctocog alfa, previously known as BIVV001 (rFVIIIFc-VWF-XTEN), in patients with hemophilia A. Efanesoctocog alfa, a novel and...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Food and Drug Administration (FDA) | Haemophilia | Hemophilia | Pharmaceuticals